When Antonio Silva (18-5-1) and Mark Hunt (9-8-1) stepped into the octagon at UFC Fight Night 33, they made one of the best fights in mixed martial arts history. Their epic five round battle has even earned status as a candidate for a “2013 Fight of the Year” award.
Unfortunately, recent reports by MMA Junkie have confirmed that Silva failed his post-fight drug test.
“Silva is on a medically approved regimen of testosterone replacement therapy (TRT), and had been in compliance with therapeutic guidelines on all pre-fight tests performed prior to the event,” a statement issued by a UFC rep read. “The results of his test on the day of the event indicated a level of testosterone outside of allowable limit. Silva has been informed that the elevated testosterone level is a violation of the UFC Fighter Conduct Policy and his Promotional Agreement with Zuffa.”
MMA Junkie also reported that Silva’s $50,000 “Fight of the Night” bonus will be awarded to Hunt instead. And his draw will also be changed to a “no contest.” As for Hunt, the bout on his record will remain a draw.
The precise reason for Silva’s drug test failure is not certain. According to reports, his testosterone levels were very low before the event, so his doctor increased the frequency of his TRT dosage. It’s important to note that this isn’t the first time he’s failed a drug test.
Silva has a rare condition called acromegaly — more commonly known as gigantism. He failed a drug test in 2008 after his tests revealed the presence the steroid boldenone. He tried to defend himself in court to no avail when his attorney argued that the presence of boldenone in his system was caused by a legal supplement that contained the steroid. Silva’s manager claimed that he used the supplement to treat his gigantism. The court didn’t buy it and Silva lost his case.
The details of his latest drug test haven’t been revealed yet. So as of now, we’re not sure what contributed to him failing. But we do know that his nine-month suspension and $50,000 pay cut won’t be making him very happy.